Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01627288 · ClinicalTrials.gov registry record · NA
Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)
A NA study of Cancer of the Cervix and Cervical Neoplasms, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01627288 is a NA study of Cancer of the Cervix and Cervical Neoplasms that has completed, run by Duke University. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01627288, a NA study of Cancer of the Cervix and Cervical Neoplasms, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).
Conditions Studied
Interventions
- RADIATION Boost radiation
Study Locations (1)
North Carolina
- Radiation Oncology, DUMC - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-06-04 |
| Est. Completion | 2019-11-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01627288
The ClinicalTrials.gov registry entry for NCT01627288 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer of the Cervix appearing as the primary indexed condition, and to 1 intervention - of which Boost radiation is the first listed.
NCT01627288 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01627288 about?
NCT01627288 is a clinical study titled "Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)". The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).
What is the current status of trial NCT01627288?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2012-06-04. Estimated completion is 2019-11-16.
What conditions does trial NCT01627288 study?
This clinical trial studies the following conditions: Cancer of the Cervix, Cervical Neoplasms.
What interventions are being tested in trial NCT01627288?
The interventions under investigation include: Boost radiation (RADIATION).
Who is sponsoring clinical trial NCT01627288?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01627288 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of the Cervix
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.